Abstract:
There is a need for the development of additional prognostic melanoma
(e.g., head and neck melanoma) biomarkers to stratify melanoma
patients and reliably identify high-risk subgroups with the aim of
providing effective personalized therapy.
Biomarkers play an important role in the diagnosis and prognostic
classification of various types of cancer and may be indicators of
biological or pathological processes or responses to exposure or
intervention, providing a physician with the data helpful for future
decision making with regard to patient management.
The advent of novel treatments and modalities for treating various stages
of the disease with a notable objective response-to-survival ratio gave
us good reason, in this review, to emphasize non-histological serological
biomarkers for the correction and improvement in the efficacy of
treatment as well as the prognosis of survival in patients with head and
neck melanoma.
